TD Asset Management Inc Sells 53,200 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

TD Asset Management Inc decreased its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 35.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 95,006 shares of the company's stock after selling 53,200 shares during the quarter. TD Asset Management Inc owned 0.16% of Apogee Therapeutics worth $3,738,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. New York State Common Retirement Fund grew its position in shares of Apogee Therapeutics by 113.3% during the 4th quarter. New York State Common Retirement Fund now owns 8,969 shares of the company's stock valued at $251,000 after acquiring an additional 4,764 shares during the period. Swiss National Bank purchased a new stake in Apogee Therapeutics in the fourth quarter worth about $922,000. Jump Financial LLC bought a new position in shares of Apogee Therapeutics in the fourth quarter worth about $513,000. Franklin Resources Inc. lifted its position in shares of Apogee Therapeutics by 9.3% during the 4th quarter. Franklin Resources Inc. now owns 1,089,780 shares of the company's stock valued at $30,448,000 after buying an additional 92,423 shares in the last quarter. Finally, Artia Global Partners LP bought a new position in shares of Apogee Therapeutics during the 4th quarter valued at approximately $290,000. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics Trading Down 2.8 %

Apogee Therapeutics stock traded down $1.43 during midday trading on Thursday, hitting $49.19. The stock had a trading volume of 269,312 shares, compared to its average volume of 515,093. Apogee Therapeutics, Inc. has a 52-week low of $14.19 and a 52-week high of $72.29. The company has a market capitalization of $2.21 billion, a PE ratio of -9.37 and a beta of 2.75. The firm's fifty day moving average is $46.70 and its two-hundred day moving average is $49.38.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.60). As a group, equities research analysts predict that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Carl Dambkowski sold 5,995 shares of the business's stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total value of $225,412.00. Following the transaction, the insider now directly owns 294,793 shares in the company, valued at $11,084,216.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Carl Dambkowski sold 5,995 shares of the business's stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total value of $225,412.00. Following the transaction, the insider now owns 294,793 shares of the company's stock, valued at $11,084,216.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael Thomas Henderson sold 40,000 shares of the company's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $47.62, for a total transaction of $1,904,800.00. Following the transaction, the chief executive officer now owns 1,394,487 shares of the company's stock, valued at approximately $66,405,470.94. The disclosure for this sale can be found here. In the last quarter, insiders sold 120,995 shares of company stock worth $5,218,774. Corporate insiders own 36.10% of the company's stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.